Tislelizumab + Chemotherapy vs Chemotherapy Alone as First-line Treatment for Locally Advanced/Metastatic Nonsquamous NSCLC (nsq-NSCLC)

 ABSTRACT   09/2020

For more information about this publication, please submit a medical information request.

Tislelizumab + chemotherapy has shown antitumor activity with a favorable tolerability profile in patients (pts) with histologically confirmed nsq-NSCLC.

Nice to see you!

For newest details on our ESMO materials in a personal video meeting, please click here!
Service